BUSINESS IN IRELAND
INNOVATION
INVEST IN IRELAND
IDA IRELAND
LOCATIONS

07/04/08

featured news
Press Release

This will be the sole site for the commercial development of mAb technology for Eli Lilly worldwide. As a result, this facility is part of Lilly’s planned growth strategy and proof of our confidence in our future in the Biotechnology sector. The decision to locate this facility on our existing site at Dunderrow is due to the strong performance of the site to date, the access to top quality personnel and the support of IDA Ireland, government agencies and local community.

Dr John Lechleiter, President and CEO of Eli Lilly

07/04/2008

Eli Lilly SA
Company to begin construction of its €400m facility at its site
in Kinsale, Co Cork and enters into R&D collaboration with NIBRT


Minister for Enterprise, Trade and Employment, Micheál Martin TD today (Monday, 7th April 2008) officiated at the foundation-laying ceremony of the Eli Lilly and Company’s new Biopharmaceuticals Manufacturing facility at its premises in Dunderrow, Kinsale, Co Cork. Minister Martin was joined by Eli Lilly’s new President and CEO Dr John Lechleiter. This was Dr. Lechleiter’s first official engagement outside Indianapolis since assuming his position as CEO on April 1 2008.

At today’s ceremony Minister Martin also announced a research collaboration between NIBRT (The National Institute for Bioprocessing Research and Training) and Eli Lilly’s Biologics Research and Development Organisation (BR&D) in Indianapolis. This will involve the co-development of analytical technologies to enable the monitoring of cell culture conditions.

Eli Lilly, a global leader in biopharmaceuticals was established in Kinsale, Co Cork in 1981 and currently employs 430 people. The facility manufactures the active ingredients for a number of Eli Lilly’s most important pharmaceuticals, including Zyprexa®, for the treatment of Schizophrenia and Evista®, for the prevention of osteoporosis. In December 2006, Minister Martin announced that Eli Lilly was to invest up to €400m in a multi phase program to establish a Biopharmaceuticals Development and Manufacturing facility in Kinsale. The investment, which was supported by IDA Ireland, will require up to 200 jobs in the next 5 years.

The Minister laid the first stone on the foundation of the building which will produce medicines to treat illnesses including cancer, diabetes and Alzheimer’s disease. In addition, laboratories, to support the technology transfer and future process development work, have already been commissioned and will be fully operational by the end of 2008.

Minister Martin said, “It is an exciting day for the staff and management of Eli Lilly in Kinsale to be laying the physical foundations for this new biopharmaceutical manufacturing building. I was delighted to make this announcement for the company in 2006 - and the fact that the Irish facility was chosen for such a strategic investment against strong global competition further strengthened our position as a leading location for major biopharmaceutical activity outside the US. Eli Lilly’s Irish operation is poised to become the centre of excellence in Biopharmaceutical manufacturing technology for the company which will represent an increasing percentage of its medicines in the future.”

Dr John Lechleiter, President and CEO of Eli Lilly said “After 25 years of successful manufacturing in Kinsale, this significant diversification of the site into a new technology platform (monoclonal antibodies mAb) will allow it to develop and manufacture a new generation of products for the corporation and for patients around the world. This will be the sole site for the commercial development of mAb technology for Eli Lilly worldwide. As a result, this facility is part of Lilly’s planned growth strategy and proof of our confidence in our future in the Biotechnology sector. The decision to locate this facility on our existing site at Dunderrow is due to the strong performance of the site to date, the access to top quality personnel and the support of IDA Ireland, government agencies and local community.”

Minister Martin continued “In 2005, IDA determined that if Ireland was to continue to compete for international large-scale biopharmaceutical investments, there was a strategic competitive need to establish a state of the art industry-focused centre in Biomanufacturing and Bioprocessing technology, education, training and research. NIBRT was established to fulfil this need.” The Minister concluded “The purpose of NIBRT is to give Ireland a competitive advantage and act as a magnet of attraction for further significant investment in the biopharmaceutical industry in Ireland from both overseas and indigenous companies. This collaboration with Eli Lilly is an example of what was envisioned for NIBRT and we are looking forward to witnessing the fruits of this partnership as it progresses.”

About Eli Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Eli Lilly and Company is available at www.lilly.com.

For further information:

Eli Lilly media contact – Donal Johnson, 021 4702293

Eli Lilly HR and Supplier contact – Donal Johnson, 021 4702293

IDA Ireland - Ruth Croke, Press & PR Manager 01 6034200/ 087 4195051 ruth.croke@ida.ie

Department of Enterprise, Trade and Employment - Press Office Tel: 01- 6312200

Jerry O’Connor, Press Advisor, Department of Enterprise, Trade and Employment
087 6630338/ 01631220

IDA Landscape App

IDA Landscape App

It's the perfect tool for researching and investigating Ireland's business landscape. Full of information about companies and examples of why Ireland is the right place for your business.

Download IDA Landscape App
  • Newsletter

Subscribe to our press releases and newsletters: